COVID-19: Analysis of the Emerging Disease Landscape - March 2020

COVID-19: Analysis of the Emerging Disease Landscape - March 2020

  • March 2020 •
  • 56 pages •
  • Report ID: 5881500 •
  • Format: PDF
COVID-19: Analysis of the Emerging Disease Landscape - March 2020

Summary
The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space.The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions.

A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Scope
- Global epidemiology metrics and trends
- Snapshot of epidemiological trends to date in the top three most-affected countries
- An overview of the pipeline for antivirals and vaccines
- Summary of available efficacy data
- An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- Highlights in deal-making trends, particularly public-private partnerships
- Spotlight on social media coverage

Reasons to Buy
- Global epidemiology metrics and trends
- Snapshot of epidemiological trends to date in the top three most-affected countries
- An overview of the pipeline for antivirals and vaccines
- Summary of available efficacy data
- An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- Highlights in deal-making trends, particularly public-private partnerships
- Spotlight on social media coverage
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.